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Abstract Inherited disorders of mitochondrial energy metab-
olism form a large and heterogeneous group of metabolic
diseases. More than 250 gene defects have been reported to
date and this number continues to grow. Mitochondrial dis-
eases can be grouped into (1) disorders of oxidative phosphor-
ylation (OXPHOS) subunits and their assembly factors, (2)
defects of mitochondrial DNA, RNA and protein synthesis,
(3) defects in the substrate-generating upstream reactions of
OXPHOS, (4) defects in relevant cofactors and (5) defects in
mitochondrial homeostasis. Deficiency of more than one re-
spiratory chain enzyme is a common finding. Combined de-
fects are found in 49% of the known disease-causing genes of
mitochondrial energymetabolism and in 57% of patients with
OXPHOS defects identified in our diagnostic centre. Com-
bined defects of complexes I, III, IV and V are typically due
to deficiency of mitochondrial DNA replication, RNA metab-
olism or translation. Defects in cofactors can result in com-
bined defects of various combinations, and defects of mito-
chondrial homeostasis can result in a generalised decrease of
all OXPHOS enzymes. Noteworthy, identification of combined
defects can be complicated by different degrees of severity of
each affected enzyme. Furthermore, even defects of single re-
spiratory chain enzymes can result in combined defects due to
aberrant formation of respiratory chain supercomplexes. Com-
bined OXPHOS defects have a great variety of clinical mani-
festations in terms of onset, course severity and tissue involve-
ment. They can present as classical encephalomyopathy but
also with hepatopathy, nephropathy, haematologic findings
and Perrault syndrome in a subset of disorders.
Introduction
Mitochondria are cellular organelles essential for aerobic en-
ergy metabolism. Proper functioning of mitochondrial energy
generation depends on numerous factors. It is assumed that
more than 5 % of the human genome plays a role in this
metabolism. Indeed, defects involving more than 250 genes
(Fig. 1) have been identified to date, making disorders of
mitochondrial energy metabolism the most heterogeneous
metabolic disease group.
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At the heart of mitochondrial energy metabolism is the
respiratory chain, which uses the reduced substrates NADH,
FADH2, ubiquinol and ferrocytochrome c in a step-wise man-
ner to finally react with molecular oxygen to produce H2O and
establish a proton gradient across the inner mitochondrial
membrane. In the final step, the F1FO-ATP synthase uses the
proton gradient to generate the ubiquitous cellular energy car-
rier ATP. The whole cascade of reactions is called oxidative
phosphorylation (OXPHOS).
All five enzyme complexes of OXPHOS consist of multi-
ple protein subunits, in total approximately 75 protein sub-
units. The complexes depend on several cofactors and the
specific lipid environment of the inner mitochondrial mem-
brane to form supramolecular aggregates, which in turn influ-
ence the shape of this membrane. Importantly, 13 protein sub-
units of the OXPHOS enzymes are encoded by the small
mitochondrial genome (mtDNA), which is a specific feature
of mitochondria and distinguishes them from other cellular
organelles in mammalian cells (Schon et al 2012). Although
the number of protein-coding genes in mtDNA is small and
their functions are limited to OXPHOS, the presence of the
mitochondrial genome necessitates having mitochondrial
machinery for replication, transcription, RNA processing,
RNA modification and translation, complete with its own
ribosomes.
Defects of oxidative phosphorylation
Biochemical investigation of mitochondrial energy metabo-
lism in patient samples dates back to the 1960s, and distinct
defects in OXPHOS have been identified affecting either sin-
gle enzyme complexes or combinations of complexes.
In general, defects of mitochondrial energymetabolism can
be grouped into the following five categories (Fig. 1):
1. Isolated defects of OXPHOS subunits or assembly
factors.
2. Defects of mitochondrial DNA, RNA and protein synthe-
sis (including replication, nucleotide metabolism, RNA
processing and modification and translation).
3. Disorders in the substrate-generating upstream reactions
of OXPHOS (pyruvate dehydrogenase complex, Krebs
Fig. 1 Gene defects (n=251) of mitochondrial energy metabolism associated with human disease. Gene defects that usually present as combined
OXPHOS defects are highlighted in yellow (n=123)
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cycle, fatty acid beta-oxidation, substrate import and
anaplerosis).
4. Defects in cofactors of OXPHOS and other enzymes of
mitochondrial energy metabolism.
5. Defects in the homeostasis of mitochondria, including
their biogenesis, lipid processing, protein import, fis-
sion/fusion, and quality control.
Furthermore, defects due to inhibition, e.g. by H2S in the
case of ETHE1 deficiency and inhibition of cytochrome c
oxidase (Tiranti et al 2009) or inhibition of mitochondrial
protein import by mutated huntingtin (Yano et al 2014), have
been reported.
Combined oxidative phosphorylation defects
in diagnostics
Combined OXPHOS defects are a very common finding in
the diagnosis of disorders of mitochondrial energy metabo-
lism (Scaglia et al 2004; Gibson et al 2008; Honzik et al
2012). In the patients seen by the diagnostic centre at the
Department of Paediatrics in Salzburg, combined OXPHOS
defects are by far the most frequent cause of disorders of
mitochondrial energy metabolism, with a proportion of
57.3 % (Table 1).
It is important to point out that combined OXPHOS defects
are often picked up in enzymatic measurements as isolated
defects. A well-known example is the most frequent
m.3243A>G ‘MELAS’ (mitochondrial encephalopathy lactic
acidosis and stroke-like episodes) mutation that affects the
mitochondrial tRNALeu(UUR). In muscle biopsies of these pa-
tients, an isolated complex I deficiency is a common biochem-
ical finding; however, cytochrome c oxidase-deficient fibres
can also be detected (Zierz et al 2014). Other defects are de-
tected mainly as cytochrome c oxidase deficiency (Santorelli
et al 1997). Complex I and cytochrome c oxidase seem to be
the most vulnerable enzymes. This could be due to their larger
number of mitochondrially encoded subunits, especially in the
case of complex I (7 subunits, 2117 codons encoded in
mtDNA) or cytochrome c oxidase (3 subunits, 1003 codons)
versus ATP synthase (2 subunits, 296 codons) and complex III
(1 subunit, 380 codons) (Anderson et al 1981). Alternatively,
it could be due to different codon distributions; for example,
there is a much higher abundance of codons for tRNALeu(UUR)
in ND3 (8.7% of all codons) and ND6 (9.1% of all codons) of
complex I compared to other mtDNA-encoded proteins,
which contain less than 3 % of codons for tRNALeu(UUR).
Finally, the different sensitivities of the OXPHOS complexes
might be due to differences in the in vitro assay conditions in
different laboratories (Gellerich et al 2004) resulting in exper-
imental bias, since ATP synthesis cannot be quantified in fro-
zen samples.
Therefore, classification as a combined OXPHOS defect in
Table 1 was made on the basis of the genetic defect, which
was available in 81 % of these patients, in addition to the
results of biochemical measurements.
Typical combinations of defects of oxidative
phosphorylation
By investigation of oxidative phosphorylation enzymes in pa-
tient samples, different types of combined defects have been
identified: e.g. complex I (CI)+complex IV (CIV), CI+CIII+
IV+V, CI+CII+CIII, CI+III/CII+III, CIII+CIV or involve-
ment of all complexes (Fig. 2).
More than one enzyme can be affected due to the following
molecular mechanisms:
1. Mitochondrial DNA-related (mitochondrial replication,
transcription, RNA processing and modification, transla-
tion, large deletions of mtDNA)
2. Cofactor-related (coenzyme Q, iron-sulphur clusters,
haem/cytochromes, riboflavin)
3. Mitochondrial homeostasis-related (mitochondrial pro-
tein import, lipid metabolism, fission/fusion, mitophagy/
quality control)
4. Supercomplex related (especially complex III defects)
Combined defects related to mitochondrial DNA
The mammalian mitochondrial genome is a circular molecule
encoding 13 proteins (subunits of complexes I, III, IVand V),
two ribosomal RNAs and 22 transfer RNAs. Depending on
cell function and size, the number of mitochondria can vary,
with copy numbers of mtDNA ranging from just a few to
hundreds of thousands per nuclear genome. In contrast to the
nuclear genome, mtDNA is replicated in a cell cycle-
independent manner. Genetic defects in nuclear genes
Table 1 Number of patients in the diagnostic centre at Salzburg with
defects in mitochondrial energy metabolism
OXPHOS defect Number of patients
(% of total)
Genetic diagnoses (%)
Combined defects 177 (57.3 %) 143 (81 %)
Complex I 59 (19.1 %) 30 (51 %)
Complex II 1 (0.3 %) 1 (100 %)
Complex III 7 (2.3 %) 5 (72 %)
Cytochrome c oxidase 28 (9.1 %) 16 (57 %)
ATP synthesis 37 (12.0 %) 35 (95 %)
total 309 230 (74 %)
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involved in mtDNA replication, its transcription or translation
typically affect only the four OXPHOS enzymes that contain
mitochondrially encoded subunits (complexes I, III, IV, and
V) but spare complex II and citrate synthase; the latter is
commonly used in biochemical analyses as a mitochondrial
housekeeping enzyme.
Defects in mitochondrial replication
Mitochondrial DNA replication seems to require a relatively
limited number of proteins (Holt and Jacobs 2014). Up to
now, mutations in polymerase gamma (POLG gene), its ac-
cessory subunit (POLG2), and the Twinkle helicase (C10orf2)
have been reported. Furthermore, mutations of the mitochon-
drial genome maintenance exonuclease 1 (MGME1)
(Kornblum et al 2013) and the DNA replication helicase/
nuclease 2 (DNA2) (Ronchi et al 2013) have been reported
to affect mitochondrial stability. The precise role of the latter
in mtDNA metabolism is not completely understood and
needs further characterisation.
A set of enzymes is required to provide the nucleotides for
mtDNA replication: Mutations in the cytosolic enzymes ribo-
nucleotide reductase subunit M2 B (RRM2B) and thymidine
phosphorylase (TYMP) as well as themitochondrial thymidine
kinase (TK2), deoxyguanosine kinase (DGUOK), succinyl
CoA ligase subunit alpha (SUCLG1) and beta (SUCLA2), an
isoform of the adenine nucleotide translocator (SLC25A4),
and an inner membrane protein of unknown function
(MPV17) were reported (Copeland 2008).
All of these genetic defects affect mtDNA stability. Accu-
mulation of multiple mtDNA deletions but also point muta-
tions and mtDNA depletion are typical consequences of these
nuclear gene defects.
Defects in mitochondrial transcription, RNA processing
and modification
Mitochondrial transcription takes place from both the heavy
and light strands to produce a large polycistronic transcript,
which has to be processed in order to free the 22 tRNAs, 2
rRNAs and 11 mRNAs, of which two stay polycistronic.
Processing takes place predominately at the secondary struc-
tures formed by tRNAs. RNase P cleaves at the 5’-end of
tRNAs, followed by RNase Z cleavage at the 3’-end. Muta-
tions in HSD17B10, one of the three protein subunits of mi-
tochondrial RNase P, have been shown to result in an increase
of unprocessed primary transcripts (Deutschmann et al 2014).
Mutations in ELAC2, the mitochondrial RNase Z, lead to an
accumulation of mRNAs with tRNAs attached to the 5’-ends
(Haack et al 2013). Most mitochondrial mRNAs are modified
byMTPAP-mediated polyadenylation; a mutation in this gene
resulted in a loss of polyadenylation but remarkably the
mRNAs remained oligoadenylated (Crosby et al 2010). Mu-
tations in LRPPRC, a leucine-rich pentatricopeptide repeat-
containing protein that is involved in posttranscriptional reg-
ulator of mtDNA expression, result in decreased mitochondri-
al mRNA stability (Sasarman et al 2010). The function of
PNPT1, polyribonucleotide nucleotidyltransferase 1, is still a
matter of debate, but it might be involved in mitochondrial
RNase P RNA import (Wang et al 2012) or part of mitochon-
drial RNA surveillance (Sarkar and Fisher 2006); mutations
result in combined respiratory chain deficiency (Vedrenne
et al 2012b).
After processing by RNase Z, the 3’-end of transfer RNAs
is modified by addition of CCA, a reaction catalysed by
TRNT1. A deficiency of this enzyme affects mitochondrial
and cytosolic tRNA modification (Chakraborty et al 2014).
Mitochondrial rRNAs, but especially tRNAs, are subject to
numerous posttranscriptional modifications catalysed by a
battery of enzymes, which are necessary to ensure proper co-
don–anticodon interaction, folding and stability (Suzuki and
Nagao 2011). Mutations affecting tRNA modification have
been reported in PUS1 (Bykhovskaya et al 2004), TRMU
(Zeharia et al 2009), MTO1 (Ghezzi et al 2012), GTPBP3
(Kopajtich et al 2014) and TRIT1 (Yarham et al 2014),
resulting in decreased de novo protein synthesis in
mitochondria.
Defects in mitochondrial translation
Mitochondria have their own ribosomes with at least 80 ribo-
somal proteins forming the large 39S and small 28S subunits
Fig. 2 Types of combined
respiratory chain defects (typical
results) and their causes
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(Rackham and Filipovska 2014). Mutations have been report-
ed in MRPL3 (Galmiche et al 2011), MRPL12 (Serre et al
2013), MRPL44 (Carroll et al 2013), MRPS16 (Miller et al
2004) and MRPS22 (Saada et al 2007) so far. The 12S and
16S ribosomal RNAs are encoded on the mitochondrial DNA.
For translation, 22 mitochondrially encoded tRNAs are re-
quired, which are hot spots for mutation. More than 250 path-
ogenic mutations of mitochondrial tRNAs have been identi-
fied (Ruiz-Pesini et al 2007). Loading of each tRNAwith its
proper amino acid necessitates 19 aminoacyl tRNA synthe-
tases, 17 of which are specific for mitochondria and two
(GARS, KARS) are shared between the cytosol and mito-
chondria. With the exception of PARS2 and WARS2, muta-
tions have been reported in all of these aminoacyl tRNA
synthases (Diodato et al 2014; Hallmann et al 2014;
Schwartzentruber et al 2014; Vanlander et al 2014). Like in
bacteria, nascent mitochondrial proteins start with N-
formylmethionine, which is generated by methionyl-tRNA
formyltransferase (MTFMT) using the substrates Met-
tRNAMet and 10-formyl-tetrahydrofolate. Mutation of this
gene leads to a translation deficiency in mitochondria (Tucker
et al 2011). Mitochondrial translation is regulated by several
factors, and mutations affecting this process have been found
in the translation elongation factors G (GFM1 gene, (Coenen
et al 2004)), Ts (TSFM gene, (Smeitink et al 2006)) and Tu
(TUFM gene, (Valente et al 2007)), in the release factor
C12orf65 (Antonicka et al 2010), and in the conserved mito-
chondrial membrane protein RMND1, whose function in mi-
tochondrial translation is uncharacterised (Garcia-Diaz et al
2012; Janer et al 2012).
Large deletions of the mitochondrial DNA
The midpoint of single large deletions of mtDNA is usually
located between positions 9000 and 13,500, with deletion
sizes ranging between 2 and 9 kb (Grady et al 2014). Typical-
ly, large deletions cover several protein-coding genes and also
affect tRNAs. Large deletions are thereby a classic example of
combined OXPHOS defects due to loss of protein-coding
genes in combination with tRNA deficiency that results in
mitochondrial translation defects.
Combined defects due to deficiency of cofactors
Numerous cofactors play an essential role in mitochondrial
energy metabolism. Some of these cofactors are required for
several of the respiratory chain enzymes like coenzyme Q,
iron-sulphur clusters, riboflavin and haem. Their deficiency
typically results in defects of more than one respiratory
enzyme.
Coenzyme Q deficiency
This cofactor, which is also called ubiquinone, is a lipid com-
pound consisting of a quinone group that can absorb one
(forming a semiquinone) or two electrons and a side chain
of variable isoprenoid residues. In the case of human ubiqui-
none, the side chain consists of ten isoprenoid residues
(CoQ10). CoQ10 carries electrons from complex I and com-
plex II to complex III, but is also necessary for other reactions
like those catalysed by the electron-transferring-flavoprotein
dehydrogenase (ETFDH) (involved in fatty acid oxidation and
amino acid catabolism) and the mitochondrial glycerol-3-
phosphate dehydrogenase (part of the redox transporting
glycerol-3-phosphate shuttle). The synthesis of coenzyme Q
takes place in mitochondria, and several defects of coenzyme
Q biosynthesis affecting either enzymatic steps (PDSS1,
PDSS2, COQ2, COQ6), regulatory proteins (ADCK3,
ADCK4, COQ4) or an unknown function (COQ9) have been
reported (Desbats et al 2014; Brea-Calvo et al 2015). Typical-
ly these defects present with defects of complex I+III and II+
III, activities that require coenzyme Q (Lopez et al 2006). In
addition to defects in CoQ10 synthesis, secondary deficiency
has been found in several other genetic disorders: APTX,
(Quinzii et al 2005), ETFDH, (Gempel et al 2007), BRAF,
(Aeby et al 2007), methylmalonic acidaemia, (Haas et al
2009) and ANO10 (Balreira et al 2014). Supplementation
with CoQ10 can improve the outcome of several of these de-
fects significantly (Quinzii et al 2014).
Defects in iron sulphur cluster synthesis
Iron sulphur (FeS) clusters are an ancient compound
consisting of varying proportions of iron and sulphur forming
an oligomeric molecule with alternating iron and sulphur
atoms, in humans predominantly rhombic [2Fe-2S] and
cubane [4Fe-4S]. The initial part of FeS cluster biosynthesis
takes place in a stepwise process in mitochondria with cyste-
ine as the sulphur donor and iron in the form of a Fe2+ ion
(Stehling et al 2014). Due to their capability to accept and
donate electrons, FeS clusters are involved in numerous redox
reactions, including those carried out by respiratory chain
complexes I, II and III but also aconitase from the Krebs cycle
and lipoic acid synthetase. The latter is necessary for mito-
chondrial lipoic acid synthesis and therefore essential for 2-
ketoacid dehydrogenases like pyruvate dehydrogenase and α-
ketoglutarate dehydrogenase (Mayr et al 2014).
Mutations in the early steps of FeS biosynthesis affecting
FDX1L, FXN, ISCU, NFS1 or LYRM4 result in deficiency of
the respiratory chain complexes I, II, III and aconitase but
affect lipoic acid synthesis to a lesser extent. Mutations in
BOLA3, NFU1, IBA57 and GLRX5 result in defects of mi-
tochondrial 4Fe-4S synthesis and a pronounced deficiency of
complex II, complex I and lipoic acid synthesis but spare
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complex III and aconitase. Mutations in NUBPL result in
isolated complex I deficiency (Stehling et al 2014).
Other cofactors
Cytochromes (a, a3, b and c) with prosthetic haem groups are
essential parts of respiratory chain complexes. Deficiencies of
haem biosynthesis are known to result in several types of
porphyria (Puy et al 2010), but no involvement of the respira-
tory chain has been reported in these patients. Autosomal
dominant mutations have been identified in CYCS, encoding
cytochrome c, which carries electrons from complex III to
cytochrome c oxidase (Morison et al 2008). Haem c is trans-
ferred to apo-cytochrome c by holocytochrome c synthase
encoded by the X-chromosomal HCCS gene. Mutations have
been identified in heterozygous females and in a male with
somatic mutations (van Rahden et al 2014). Recently, a muta-
tion of FLAD1, which encodes the FAD synthase, was iden-
tified by a genetic screening approach in a single patient with
combined complex I and cytochrome c oxidase deficiency
(Taylor et al 2014). A combined defect of complex I and I+
III has been identified in SFXN4 deficiency, affecting an inner
membrane protein with a potential role in iron transport
(Hildick-Smith et al 2013).
Defects in mitochondrial homeostasis
Mitochondrial homeostasis involves several essential aspects
of mitochondrial biogenesis, lipid synthesis, protein import,
fission and fusion, quality control and targeted degradation.
Defects in mitochondrial lipid synthesis
Mitochondrial membranes consist of a high proportion of non-
bilayer forming lipids. De novo synthesis of the phospholipids
phosphat idylethanolamine, cardiol ipin (CL) and
phosphatidylglycerol takes place in mitochondria (Mayr
2014). Defects have been found in tafazzin, which is encoded
by the X-chromosomal TAZ gene, and cause Barth syndrome
(MIM 302060) and combined OXPHOS defects (Karkucinska-
Wieckowska et al 2013). Tafazzin is involved in remodelling of
CL. Mutations in the mitochondrial co-chaperone DNAJC19
are associated with cardiomyopathy and 3-methylglutaconic
aciduria. DNAJC19 acts in a complex with prohibitin (PHB).
Absence of this complex leads to the accumulation of CL spe-
cies with altered acyl chains similar to those in Barth syndrome
(Richter-Dennerlein et al 2014). De novo synthesis of CL starts
from phosphatidic acid (PA). PA formation from diacylglycerol
seems to be limiting in AGK deficiency, which is the genetic
cause of Sengers syndrome (MIM 212350) (Mayr et al 2012)
with combined deficiency of complex I and the adenine nucle-
otide translocator (Haghighi et al 2014). An abnormal fatty acid
composition of phosphatidylglycerol and decreased
bis(monoacylglycero)phosphate (BMP) concentration have
been found in patients with MEGDEL syndrome and SERA
C1 deficiency (Wortmann et al 2012). Abnormal lipid compo-
sition, especially of CL, affects the activity of OXPHOS en-
zymes and also of adenine nucleotide translocator (Mayr 2014).
Deficiencies in protein import, processing and quality control
The highly conserved mitochondrial protein import machin-
ery has been mostly unravelled by studies in yeast (Neupert
and Herrmann 2007). In stark contrast to the complexity of
this system, only a few defects have been identified, including
deficiency of the X-chromosomally encoded subunit
TIMM8A of the inner membrane translocase associated with
Mohr-Tranebjaerg syndrome (MIM 304700) (Jin et al 1996).
A deficiency of the disulphide relay system protein GFER is
associated with cataract and combined respiratory chain defi-
ciency (Di Fonzo et al 2009).
Defects of the X-prolyl aminopeptidase 3 encoded by
XPNPEP3 result in improper N-terminal protein processing
and instability of several subunits of OXPHOS enzymes
(Vogtle et al 2009; O'Toole et al 2010).
Protein quality control in mitochondria involves several
pathways. Mutations have been identified in the following:
HSPD1, encoding the conserved heat shock protein 60
(Hansen et al 2002); CLPP, a caseinolytic mitochondrial ma-
trix peptidase proteolytic subunit (Jenkinson et al 2012);
SPG7, encoding a component of the m-AAA protease termed
paraplegin (Casari et al 1998); and AFG3L2, encoding the
catalytic subunit of the m-AAA protease (Cagnoli et al
2006). Defective respiration has been demonstrated in
AFG3L2 complementation studies in yeast (Di Bella et al
2010). Multiple deletions of mtDNA have been identified in
muscle biopsies of patients with SPG7 deficiency (Pfeffer et al
2014; Wedding et al 2014) and also with AFG3L2 deficiency
(Gorman et al 2014).
Defects of mitochondrial fission and fusion
Mitochondria are dynamic organelles which undergo fission
and fusion. The protein machinery needed for fission is widely
conserved between mitochondria and peroxisomes (Schrader
et al 2012). A central protein in fission is the dynamin 1-like
protein DNM1L, frequently also termed Drp1, which forms a
ring structure around mitochondria to promote fission. Het-
erozygous mutations cause deficiency in mitochondrial and
peroxisomal fission (Waterham et al 2007). Mutations have
also been identified in the mitochondrial fission factors MFF
and GDAP1, leading to impaired mitochondrial fission and
respiratory chain deficiency (Cassereau et al 2009;
Shamseldin et al 2012).
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Defects of mitochondrial fusion have been linked toMFN2
(mitofusin 2), a dynamin-like GTPase protein enriched at the
endoplasmic reticulum–mitochondria interface, and to OPA1,
also a dynamin-like GTPase protein located in the inner mi-
tochondrial membrane and involved in several processes, in-
cluding mitochondrial fusion. Mutations in these two proteins
result in multiple deletions of mtDNA and combined
OXPHOS deficiency (Hudson et al 2008; Rouzier et al 2012).
Combined defects related to genes with unclear
mitochondrial function
The precise mitochondrial functions of some proteins that
cause combined OXPHOS defects are not yet clear. The X-
chromosomally encoded AIFM1, well known as an apoptosis-
inducing factor, seems to have a mitochondrial function as an
NADH oxidoreductase; however, the association with
OXPHOS deficiency is not well understood. Similarly the
nature of the cytochrome c oxidase decrease in APOPT1 de-
ficiency, a mitochondrial protein termed apoptogenic 1 and
known from apoptosis studies, is not well understood
(Melchionda et al 2014). CHCHD10 is a coiled-coil-helix-
coiled-coil-helix domain-containing protein of unknown func-
tion localised to the intermembrane space of mitochondria,
and its deficiency causes multiple deletions of mtDNA and
combined OXPHOS deficiency (Bannwarth et al 2014).
FBXL4, an F-box and leucine-rich repeat protein, is also an
intermembrane space mitochondrial protein of unknown func-
tion. Deficiency of FBXL4 causes a decrease of all OXPHOS
subunits but also of other mitochondrial proteins and mtDNA
(Bonnen et al 2013; Gai et al 2013). Deficiency of the mito-
chondrial protein OPA3 causes 3-methylglutaconic aciduria,
which has been found in several other defects of mitochondri-
al energy metabolism (Wortmann et al 2013), and fragmenta-
tion of the mitochondrial network (Grau et al 2013); however,
the precise function of OPA3 remains unclear. Finally, multi-
ple deletions of mtDNA have been reported in one study of a
family with Aicardi-Goutieres syndrome 5 (MIM 612952)
and SAMHD1 deficiency (Leshinsky-Silver et al 2011). The
molecular link of SAMHD1 to mitochondrial DNA is not
clear but could be related to its function in deoxynucleotide
metabolism.
Combined defects due to toxic metabolites
Accumulation of highly reactive metabolites like methacrylyl-
CoA has been reported in defects of isoleucine catabolism,
which takes place in mitochondria. This compound forms co-
valent bonds, e.g. with the sulphhydryl group of cysteine in
proteins, which can destroy enzymes (Brown et al 1982). In
fact, combined OXPHOS defects have been reported in
HIBCH- (Loupatty et al 2007) and ECHS1- (Sakai et al
2014) deficient patients. In addition to these defects, com-
bined OXPHOS deficiency has been reported in several forms
of organic aciduria like propionic acidaemia and
methylmalonic acidaemia (de Keyzer et al 2009).
Supercomplex-related multiple OXPHOS defects
In 2000 Schägger and Pfeiffer (Schagger and Pfeiffer 2000)
introduced the concept of a respirasome with oligomerisation
of the respiratory chain complexes and formation of domain
structures on the inner mitochondrial membrane. In addition,
oligomerisation of the ATP synthase has been shown, which is
also integral for inner membrane structure (Wittig and
Schagger 2008).
Mouse cells harbouring a high mutation load in cyto-
chrome b, a mitochondrially encoded subunit of complex III,
have been shown to be deficient in both complex III and
complex I (Acin-Perez et al 2004). Homozygous loss-of-
function mutations in cytochrome b have been reported in
human oncocytic tumours with a complete loss of complex I
(Gasparre et al 2008; Zimmermann et al 2011), which is clear
evidence that assembled complex III is necessary for complex
I assembly and supercomplex formation. Also a mutation in
the UQCRC2 subunit resulted in aberrant supercomplex for-
mation and deficiency of complex I in addition to complex III
(Miyake et al 2013). Similar results were found in a knock-
down cell line of Rieske iron-sulphur protein, another subunit
of complex III (Diaz et al 2012). Furthermore, a deficiency of
supercomplex formation was shown in SURF1 deficiency,
which is known to be an assembly factor of cytochrome c
oxidase (Kovarova et al 2012). Defective supercomplex for-
mation (McKenzie et al 2006) and combined OXPHOS defi-
ciency (Karkucinska-Wieckowska et al 2013) have also been
found in patients with Barth syndrome and TAZ mutations
leading to an increased lysocardiolipin pool in mitochondria.
This summary, although incomplete, demonstrates that de-
fects in single subunits of OXPHOS enzymes and individual
assembly factors but also in the lipid composition can result in
deficiency of supercomplex formation and hence a combined
OXPHOS deficiency.
Clinical presentation of combined OXPHOS defects
The clinical phenotypes associated with combined OXPHOS
defects are very heterogeneous, but in many cases encephalo-
myopathy is the main presentation. A very well-characterised
example is the most common BMELAS^mutationm.3243A>
G that can result in different clinical symptoms aside from
MELAS, including sensorineural hearing loss, (isolated) my-
opathy, cardiomyopathy, seizures, migraine, ataxia, cognitive
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impairment, bowel dysmotility, short stature, diabetes, exter-
nal ophthalmoplegia and Leigh syndrome (Nesbitt et al 2013).
Since this mutation affects the mtDNA, the mutation load is
variable and can be different in different tissues. Affected
individuals usually carry this mutation in a high proportion;
however, clinically unaffected or just mildly affected maternal
relatives who carry a high mutation load are also found in
these pedigrees (Dubeau et al 2000). Another well-studied
example of clinical heterogeneity concerns patients with mu-
tations in the POLG gene, encoding mitochondrial DNA po-
lymerase γ. The clinical features of deficiencies in this gene
include seizures and hepatopathy (Alpers disease), ataxia,
neuropathy, myopathy, chronic progressive external
ophthalmoplegia, ptosis, sensorineural deafness, parkinson-
ism and premature ovarian failure, hypogonadism and gastro-
intestinal dysmotility (Tchikviladze et al 2014). The same
causative mutation can be either autosomal recessive or dom-
inant, the latter usually resulting in delay of disease onset to
adulthood.
As illustrated by these two examples, it is not possible to
describe a general clinical picture of combined OXPHOS de-
fects. In the following, some clinical features and syndromes
are summarised that are associated with certain types of com-
bined OXPHOS and can be helpful in the diagnosis of
patients:
Hepatopathy is found only in certain defects of mitochon-
drial energy metabolism but especially in a number of com-
bined OXPHOS disorders (Table 2). Hepatic presentation is
frequently encountered in disorders of mitochondrial replica-
tion associated with POLG or C10orf2 (Twinkle); in disorders
of mitochondrial nucleotide metabolism involving DGUOK,
MPV, SUCLG1 and TRMU (usually transient infantile man-
ifestation); in aberrant translation regulation by TSFM
(Vedrenne et al 2012a) and in some cases of GFM1 deficiency,
and was also reported in patients with EARS2 (1 patient) and
FARS2 deficiency (Rahman 2013). Furthermore, hepatopathy
is also a relatively common feature in MEGDEL syndrome
with SERAC1 deficiency, which involves lipid metabolism
(Wortmann et al 1993).
Nephropathy may be an underdiagnosed sign of mito-
chondrial disease but it has been reported in several combined
OXPHOS defects. Proximal tubulopathy is a typical finding in
early onset mitochondrial DNA depletion syndrome caused
by RRM2B deficiency (Bourdon et al 2007) and was also
reported in a family with C10orf2 (Twinkle)-deficient patients
(Prasad et al 2013). Renal tubulopathy is further found in
translational defects involving SARS2, MRPS22 and TSFM
(O'Toole 2014). In coenzyme Q synthesis defects, nephrotic
syndrome (ADCK4, PDSS2, COQ2, COQ6) and tubulopathy
(COQ9) are leading features (Desbats et al 2014). Patients
with XPNPEP3 deficiency, encoding X-prolyl aminopepti-
dase 3, develop a nephronophthisis-like nephropathy but can
also involve other organs (O'Toole et al 2010). Furthermore,
tubulo in ters t i t i a l nephr i t i s and focal segmenta l
glomerulosclerosis have been associated with various mito-
chondrial tRNA mutations, and single deletions of mtDNA
have been reported to cause proximal as well as distal
tubulopathy (O'Toole 2014).
Perrault syndrome is an autosomal recessive disorder
characterised by sensorineural hearing loss in males and fe-
males and ovarian dysfunction in females. Neurologic features
have been described in some affected women (Newman et al
Table 2 Characteristic clinical manifestations found in some gene defects associated with combined OXPHOS deficiency
Hepatopathy Nephropathy Perrault syndrome Haematologic manifestation Leigh-(like)
POLG RRM2B HARS2 PUS1 TYMP
C10orf2 (Twinkle) C10orf2 (Twinkle) LARS2 YARS2 MTPAP
DGUOK TSFM CLPP TRNT1 LRPPRC
MPV MRPS22 C10orf2 (Twinkle) SFXN4 PNPT1
SUCLG1 SARS2 GLRX5 TUFM
TRMU ADCK4 FBXL4 (partially) GFM1
EARS2 COQ2 CYCS C12orf65
FARS2 COQ6 TAZ MT-TI
TSFM COQ9 MT-TL1 MT-TK
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1993). To date, mutations in five genes (CLPP, HARS2,
LARS2, C10orf2 [Twinkle] (Morino et al 2014), HSD17B4)
have been reported, with all but the last causing combined
OXPHOS deficiency.
Haematologic manifestations of combined OXPHOS de-
fects include aplastic, macrocytic or sideroblastic anaemia,
leukopenia, neutropenia, thrombocytopenia or pancytopenia.
Sideroblastic anaemia is characterised by the presence of
ringed sideroblasts in the bone marrow and can be caused by
PUS1 deficiency (affecting mitochondrial pseudouridine syn-
thase) and presenting clinically as myopathy, lactic acidosis
and sideroblastic anaemia (MLASA) (Bykhovskaya et al
2004). Deficiency of YARS2, the mitochondrial tyrosyl-
tRNA synthetase, also results in a MLASA phenotype (Riley
et al 2010). Recently, patients with mutations in TRNT1
(tRNA CCA-adding nucleotidyl transferase) have been re-
ported. Clinically they present with congenital sideroblastic
anaemia with immunodeficiency, fever and developmental
delay (SIFD) (Chakraborty et al 2014). Two patients with
either homozygous (Camaschella et al 2007) or compound
heterozygous (Liu et al 2014) mutations in GLRX5, a mito-
chondrial enzyme of iron sulphur cluster maturation also
needed for haem biosynthesis, have been described. Macro-
cytic anaemia with megaloblastic features has been reported
in patients with SFXN4 deficiency, an inner mitochondrial
membrane protein with a presumed iron transport function
(Hildick-Smith et al 2013). Thrombocytopenia has been re-
ported as a major feature in patients with autosomal dominant
CYCS deficiency of cytochrome c (Morison et al 2008; De
Rocco et al 2014). Neutropenia is associated in male patients
with Barth syndrome, caused by TAZmutations, in addition to
cardiomyopathy, skeletal myopathy, prepubertal growth delay
and a distinctive facial gestalt (Ferreira et al 1993). In addition
to global developmental delay, hypotonia and other clinical
features, neutropenia has been identified in patients deficient
in FBXL4, an intermembrane space mitochondrial protein in-
volved in mitochondrial biogenesis (Gai et al 2013). Further-
more, neutropenia has also been reported in a patient with the
common m.3243A>G mutation in the MT-TL1 gene (De
Kremer et al 2001). Pearson marrow–pancreas syndrome
(MIM 557000) is caused by deletions of mtDNA, with vari-
able generalised clinical manifestations, including
haematologic presentation with early transfusion-dependent
anaemia, neutropenia, thrombocytopenia, and, less abundant,
also ringed sideroblasts in bone marrow aspirates (Broomfield
et al 2014).
Leigh syndrome (LS, MIM 256000) is characterised by
progressive neurologic disease with motor and intellectual de-
velopmental delay, signs and symptoms of brain stem and/or
basal ganglia disease, and raised lactate (Thorburn and Rahman
1993). LS or Leigh-like presentation is most prevalent in de-
fects of OXPHOS subunits and assembly factors, but also sev-
eral combined OXPHOS defects present with this neurologic
manifestation and involve either mitochondrial nucleotide or
RNA metabolism, translation, a form of coenzyme Q deficien-
cy, and a few defects in mitochondrial homeostasis (Table 2).
Conclusion
Combined OXPHOS defects are the most frequent cause of
disorders of mitochondrial energy metabolism found in nearly
half of the known gene defects (Fig. 1) and affecting more
than 50 % of patients (Table 1).
Diagnosis of combined OXPHOS defects is complicated
by the fact that the degree of individual OXPHOS enzyme
decrease involvement is not necessarily identical among the
different gene defects and it can vary between tissues. There-
fore, combined OXPHOS defects can be picked up as isolated
defects, especially in cases with mild manifestation.
Clinically, combined OXPHOS defects are highly hetero-
geneous with a broad spectrum of possible signs even for
identical mutations (especially of the mtDNA). Several fea-
tures are restricted to a subset of genetic defects (Table 2),
which may help to pinpoint the underlying molecular cause
of a combined respiratory chain deficiency.
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